Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.

[1]  M. Bartholomä.  Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application. , 2018, Journal of labelled compounds & radiopharmaceuticals.

[2]  Y. Sakai,et al.  Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway , 2018, International journal of molecular sciences.

[3]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[4]  A. Berkenblit,et al.  Antibody-Drug Conjugates for Cancer Treatment. , 2018, Annual review of medicine.

[5]  J. Tavernier,et al.  Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma , 2017, Molecular Cancer Therapeutics.

[6]  Lestat R. Ali,et al.  Localized CD47 blockade enhances immunotherapy for murine melanoma , 2017, Proceedings of the National Academy of Sciences.

[7]  S. Loi,et al.  Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). , 2017, Breast.

[8]  N. Devoogdt,et al.  131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment , 2017, Clinical Cancer Research.

[9]  D. R. Grimes,et al.  Hypoxia imaging and radiotherapy: bridging the resolution gap , 2017, The British journal of radiology.

[10]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[11]  B. Gallez,et al.  Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical Settings , 2017, Front. Oncol..

[12]  K. Movahedi,et al.  The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages. , 2016, Antioxidants & redox signaling.

[13]  Guy Bormans,et al.  PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments , 2015, The Journal of Nuclear Medicine.

[14]  Kevin J. Harrington,et al.  The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.

[15]  Steven M. Larson,et al.  Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.

[16]  S. Muyldermans,et al.  Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer , 2014, Expert opinion on drug delivery.

[17]  S. Muyldermans,et al.  Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody , 2014, Theranostics.

[18]  S. Muyldermans,et al.  Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies , 2014, Leukemia.

[19]  M. Mazzone,et al.  Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. , 2013, Cancer cell.

[20]  P. De Baetselier,et al.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. , 2012, Cancer research.

[21]  F. Theil,et al.  Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice , 2012, British journal of pharmacology.

[22]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[23]  U. Mazurek,et al.  The hypoxic cell a target for selective cancer therapy , 2009 .

[24]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[25]  Evangelia Bolli,et al.  Novel insights in the regulation and function of macrophages in the tumor microenvironment , 2017, Current opinion in oncology.

[26]  F. Tacke,et al.  M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. , 2016, Cancer research.

[27]  P. Carmeliet,et al.  Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. , 2014, Cancer research.